Aligos Therapeutics
ALGS
33 hedge funds and large institutions have $26M invested in Aligos Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 9 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
33% more capital invested
Capital invested by funds: $19.5M → $26M (+$6.48M)
1.37% less ownership
Funds ownership: 50.92% → 49.55% (-1.4%)
11% less funds holding
Funds holding: 37 → 33 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$606K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$292K |
| 3 |
Two Sigma Investments
New York
|
+$246K |
| 4 |
LPL Financial
San Diego,
California
|
+$229K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$123K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.02M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$458K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$183K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$99.9K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$96.9K |
ALGS Hedge Fund Activity: Q3 2025 in Review
33 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q3 2025, worth a combined $26M — up 33% from $19.5M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ALGS and 5 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 11 added.
The largest buyer was Readystate Asset Management, adding an estimated $606K. The largest seller was Tang Capital Management, exiting entirely with an estimated $1.02M sold.
- 33 institutional investors held Aligos Therapeutics (ALGS) as of Q3 2025, down from 37 in Q2 2025.
- Funds reported $26M of Aligos Therapeutics stock for Q3 2025, up 33% quarter-over-quarter.
- 5 funds opened new Aligos Therapeutics positions in Q3 2025 and 9 closed out, a net change of -4 holders.
- The largest Aligos Therapeutics buyer in Q3 2025 was Readystate Asset Management, an estimated $606K added.
- The largest Aligos Therapeutics seller in Q3 2025 was Tang Capital Management, an estimated $1.02M sold.
Based on aggregated 13F filings for Q3 2025.